SCHEMBL25183997

SCHEMBL25183997

O=C(O)c1cc(-c2cc(Cl)ccc2Cl)[nH]n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.49
▸ KMT2A Q03164 5/20 0.49
▸ MAPT P10636 5/20 0.49
▸ HPGD P15428 3/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ ALOX15 P16050 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ HCAR2 Q8TDS4 3/20 0.46
▸ ALPL P05186 2/20 0.46
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ DAO P14920 1/20 0.42
▸ MARS1 P56192 1/20 0.42
▸ CNR2 P34972 1/20 0.41
▸ PIM1 P11309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25188817 0.88 ALPL (0.56) MEN1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL1413998 0.83 KMT2A (0.59) MEN1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL117667 0.80 MARS1 (0.60) SMN1; SMN2ALPLMARS1
SCHEMBL1413913 0.79 NPC1 (0.55) MEN1KMT2AMAPTSMN1; SMN2POLB
SCHEMBL3682308 0.76 KMO (0.55) MEN1KMT2AMAPTPOLBHCAR2
SCHEMBL13883208 0.76 HCAR2 (0.47) MEN1KMT2AMAPTSMN1; SMN2POLB
SCHEMBL14152313 0.75 HCAR2 (0.56) MEN1KMT2AMAPTHPGDALOX15
SCHEMBL20507163 0.73 CDH1 (0.55) MEN1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL1222694 0.72 ALOX15 (0.61) MEN1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL24424513 0.72 HCAR2 (0.41) MEN1KMT2AMAPTALOX15LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-11-13 — — US disclosed
EP-4431505-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2024-09-18 — — EP disclosed
CN-118234721-A Isoindolinone derivative with glutarimide mother nucleus and application thereof 韩国化学研究院 2024-06-21 — — CN disclosed
WO-2023085785-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF 한국화학연구원 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF CRBN, IDH1, IDH2 MEN1 2910/4885KMT2A 1899/4885MAPT 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback